Pharmaceutical Research center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Drug Dev Ind Pharm. 2013 Aug;39(8):1238-46. doi: 10.3109/03639045.2012.707207. Epub 2012 Aug 9.
The effects of type and concentration of binding agent on properties of Eudragit RS based pellets were studied.
Pellets containing ibuprofen (60%), Eudragit RS (30%), Avicel (10%) were prepared by extrusion spheronization. PVP K30, PVP K90, HPMC 6cp, HPMC K100LV or HPMC K4M were used as binders in concentrations of 2, 4 or 6% based on the total weight of formulation. The process efficiency, pellet shape, size distribution, crushing strength, elastic modulus and drug release were examined. The effect of curing on pellet properties was also investigated.
The process of extrusion spheronization became difficult with increase in binder viscosity and/or concentration. An increase in binder viscosity and/or concentration resulted in reduction in the yield of pellets, wider particle size distribution and departure from spherical shape especially in the case of HPMC binder. The crushing strength and elastic modulus of pellets decreased with increase in PVPs concentration. However this was not the case for pellets containing HPMCs. Drug release rate increased as the concentration of binder increased. Pellets containing 2%w/w of PVP K30 showed the slowest release rate. For those pellets with brittle nature, curing changed the behavior of pellet under mechanical test to plastic deformation. Yield point and elastic modulus of all formulations decreased after curing. Curing decreased the drug release rate.
Binder type and concentration significantly affected the properties of pellets. For production of sustained release ibuprofen Eudragit RS based pellets lower viscosity binders (PVP K30) with concentrations less than 4%w/w was optimum.
研究了结合剂的类型和浓度对 Eudragit RS 载药丸性质的影响。
通过挤出滚圆法制备包含布洛芬(60%)、Eudragit RS(30%)、Avicel(10%)的载药丸。PVP K30、PVP K90、HPMC 6cp、HPMC K100LV 或 HPMC K4M 用作粘合剂,浓度分别为 2%、4%或 6%,基于配方的总重量。考察了过程效率、丸形状、粒径分布、破碎强度、弹性模量和药物释放。还研究了固化对丸性质的影响。
随着结合剂粘度和/或浓度的增加,挤出滚圆过程变得困难。结合剂粘度和/或浓度的增加导致丸的收率降低、粒径分布变宽且偏离球形,尤其是在 HPMC 粘合剂的情况下。随着 PVP 浓度的增加,丸的破碎强度和弹性模量降低。然而,对于含有 HPMC 的丸则不然。随着粘合剂浓度的增加,药物释放速率增加。含有 2%w/w PVP K30 的丸显示最慢的释放速率。对于那些脆性丸,固化会改变丸在机械试验下的行为,从脆性变形变为塑性变形。所有配方的屈服点和弹性模量在固化后均降低。固化降低了药物释放速率。
结合剂的类型和浓度显著影响丸的性质。对于生产缓释 Eudragit RS 载布洛芬丸,优选低粘度粘合剂(PVP K30),浓度低于 4%w/w。